Valneva Austria Gmbh

This study is checking how long a single dose of an experimental chikungunya vaccine keeps protecting people and if it remains safe over many years. It follows about 375 adults who got the vaccine in a previous trial, checking their immunity and health annually for up to 10 years…

This study is carefully watching for side effects in 5,000 people in Brazil who have already received a new vaccine for chikungunya virus. The main goal is to understand how common certain health concerns are after vaccination, including heart issues and joint pain. Researchers w…

This study aims to measure how well the VLA1553 vaccine prevents chikungunya virus disease in real-world conditions in Brazil. Researchers will compare about 1,200 people who develop chikungunya-like symptoms, checking if vaccinated individuals are less likely to test positive fo…

This study aimed to test a vaccine designed to protect children from the chikungunya virus, a painful mosquito-borne illness. It planned to enroll at least 3,000 healthy children aged 1 to 11 years to receive either the experimental vaccine or a comparator vaccine. The main goal …

This study is measuring how many people in about 10 Brazilian communities already have natural immunity to the chikungunya virus. Researchers are surveying over 5,300 residents aged 2 years and older before a new pilot vaccination program begins. The goal is to understand how pre…